R297
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 10
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- ANGIOGENESIS+0.490
- HEDGEHOG_SIGNALING+0.430
- MYOGENESIS+0.370
- APICAL_SURFACE+0.330
- PANCREAS_BETA_CELLS+0.320
- SPERMATOGENESIS+0.290
- KRAS_SIGNALING_UP+0.260
- APICAL_JUNCTION+0.220
- COAGULATION+0.180
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.530
- INTERFERON_GAMMA_RESPONSE-0.430
- PROTEIN_SECRETION-0.370
- PI3K_AKT_MTOR_SIGNALING-0.340
- OXIDATIVE_PHOSPHORYLATION-0.320
- MYC_TARGETS_V2-0.300
- DNA_REPAIR-0.290
- TGF_BETA_SIGNALING-0.280
- MYC_TARGETS_V1-0.230
- P53_PATHWAY-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG686 | — | — | 0.879 |
| 2 | R99 | — | — | 0.816 |
| 3 | MNG934 | — | — | 0.783 |
| 4 | MNG242 | — | — | 0.766 |
| 5 | SRR12202428 | — | — | 0.748 |
| 6 | TCGA-55-A490-01A-11R-A466-07 | — | cohortA1 | 0.742 |
| 7 | 82938 | EPN | Supratentorial EPN | 0.742 |
| 8 | R114 | — | — | 0.741 |
| 9 | R81 | — | — | 0.740 |
| 10 | MNG313 | — | — | 0.733 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.430 | Inavolisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.330 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| E2F_TARGETS | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.110 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |